EDGC to launch liquid biopsy screening service, technology for early detection of cancers, this autumn
- Font Size
- Font Size Down Font Size Up
- Liquid biopsy drawing attention to prevent any recurrence in patients with cancer and early detect it
- Liquid biopsy, achievement of developing the most difficult technology
EONE-DIAGNOMICS Genome Center(EDGC), a global company in genetic analysis, has announced to release the liquid biopsy screening service this autumn. The service is a non-invasive liquid biopsy technology which has drawn attention as the most promising futuristic diagnosis technology for the next-generation with the development of NGS technology.
A liquid biopsy technology is a technology that Grail, Illumina Inc. spin out, and others has raised about 1.8 billion dollars’ funds and has developed, and it is useful for preventing any recurrence in patients with cancer and early detecting cancer for the people.
Especially, a liquid biopsy screening technology is known as the most difficult liquid biopsy technology that should be able to early detect various cancers with a simple blood test from the people without any signs or symptoms, and it is only capable through comprehensive analysis of samples, various biomarkers measurements and precise algorithms.
EDGC has been developing the liquid biopsy technology for lung cancer, colorectal cancer and breast cancer, interworking with domestic and overseas university hospitals and has decided to commercialize it by resulting in excellent achievements in clinical experiments recently. The liquid biopsy screening service commercialized this time would be provided to the global market through CLIA certification in the United States. Also, it would predict risk of cancers statistically and detect even microscopic factors leading to cancers, analyzing both inherent risk of cancers and acquired biomarkers simultaneously.
In this regards, EDGC has proceeded a presentation titled 'NGS Analysis Methods and Examples for Liquid Biopsy' at the International Symposium of Korean Society of Integrative Oncology which was held in South Korea on October 14th. The symposium covered anti-cancer immunotherapy, the Nobel Prize-winning field, and greatest scholars such as Dr. Gary Deng of the Memorial Sloan Kettering Cancer Center in the United States and Prof. Ping-Ping Li of Peking University Cancer Hospital in China participated in it and discussed about integrated cancer treatments. Therefore, it became the opportunity for EDGC to show its liquid biopsy technology to them.
Ph.D. Sung Hoon Lee, a chief technology officer in charge of the development for the liquid biopsy screening technology, said that the multi-omics liquid biopsy method is an innovative method to overcome constraints and limitations of existing cancer diagnosis tests by combining protein and nucleotide sequencing analysis and by performing quantitative and qualitative analysis simultaneously. He explained that it was able to provide the multi-faceted service by accumulated experiences of genomic data analysis algorithms and non-invasive prenatal diagnosis that EDGC has developed so far.
Meanwhile, Variable Signal-Amplifying Algorithm(VarSAMP), a core algorithm of the technology, and Multivariant Regression are patent-pending, and other quantitative and qualitative analysis methods and complex analysis are in patent preparations.
Also, he said that the method could not only detect cancers with high accuracy but also allow accurate measurement with a few of analysis data since it maximizes sensitivity but does not lower specificity. Therefore, it has the advantage to perform accurate analysis with much lower cost as compared to methods overseas competitors use. He expressed high confidence about it.
After announcing the technology development, EDGC has the plan to perform global researches and additional clinical cooperation in several countries. For this, it would recruit clinical participants from South Korea, the United States and China.
With this clinical participation, EDGC would promote a campaign to prepare for a healthy 100-year-old age by early detecting cancers as well as by apprehending comprehensive risk.
*Multi-omics: a biological analysis approach in which the data sets are multiple omes such as genome, proteome, transcriptome, epigenome and microbiome